Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
5 hedge funds and large institutions have $20K invested in Biostar Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
29% less funds holding
Funds holding: 7 → 5 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
89% less capital invested
Capital invested by funds: $189K → $20K (-$169K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.17K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$327 |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$68K |
| 2 |
Morgan Stanley
New York
|
-$54.2K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$27K |
| 4 |
Barclays
London,
United Kingdom
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $18K | +$6.17K | +3,548 | +45% |
|
|
2
UBS Group
Zurich,
Switzerland
| $2K | +$327 | +188 | +19% |
|
|
3
Morgan Stanley
New York
| – | -$54.2K | -31,150 | -100% |
|
|
4
JP Morgan Chase
New York
| – | -$68K | -29,282 | Closed |
|
|
AIM
5
Acrospire Investment Management
Chicago,
Illinois
| – | -$27K | -11,740 | Closed |
|
|
6
Barclays
London,
United Kingdom
| – | -$2K | -1,000 | Closed |
|
|
AG
7
Advisor Group
Phoenix,
Arizona
| – | +$68 | +39 | New |
|
BSPM Hedge Fund Activity: Q2 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2017, worth a combined $20K — down 89% from $189K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BSPM and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Acadian Asset Management, adding an estimated $6.17K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $68K sold.
- 5 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2017, down from 7 in Q1 2017.
- Funds reported $20K of Biostar Pharmaceuticals, Inc. stock for Q2 2017, down 89% quarter-over-quarter.
- 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q2 2017 and 3 closed out, a net change of -2 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2017 was Acadian Asset Management, an estimated $6.17K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q2 2017 was JP Morgan Chase, an estimated $68K sold.
Based on aggregated 13F filings for Q2 2017.